WHITEHOUSE STATION (dpa-AFX) - Merck (MRK) announced the company's investigational vaccine for Ebola Zaire, V920, has been granted Breakthrough Therapy Designation from the U.S. FDA, and PRIME (PRIority MEdicines) status from the the European Medicines Agency.
V920 was initially engineered by scientists from the Public Health Agency of Canada and subsequently licensed to NewLink Genetics. In late 2014, NewLink licensed V920 to Merck. Merck is responsible for the research, development, manufacturing, and regulatory efforts in support of V920.
Copyright RTT News/dpa-AFX